An open-label phase 1 clinical trial has been initiated to explore the therapeutic efficacy of CAR2 anti-CD38 A2 CAR T cells when used as a monotherapy for the management of relapsed and refractory multiple myeloma patients (NCT03464916) [69]. Here, CD38 is linked to plasma cell myeloma.